The FDA expands Palynziq approval to include pediatric patients aged 12 years and older with phenylketonuria and uncontrolled blood Phe levels.
Background Gut bacteria have been implicated in a wide range of health conditions, yet their potential role in preventing and treating muscle-wasting disorders remains largely unexplored. Objective We ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results